Amicus’ Galafold wins US approval
Amicus Therapeutics’ Galafold has been approved in the US as the first oral medication for the treatment of adults with Fabry disease.
Read More
Tag: Galafold
Amicus kicks off launch of Galafold in the UK
Amicus Therapeutics has kicked off the commercial launch of its rare disease therapy Galafold in the UK after it was endorsed for reimbursement within the NHS by the National Institute for Health and Care Excellence’s Highly Specialised Technologies Evaluation Committee.
Read More
Final NICE yes for Amicus’ Fabry disease drug
Cost regulators for NHS therapies in England and Wales have now published final guidelines endorsing the use of Amicus Therapeutics’ Galafold for treating the rare genetic disorder Fabry disease.
Read More
NICE backs Amicus’ Galafold for Fabry disease
The National Institute for Health and Care Excellence is backing National Health Service use of Amicus Therapeutics’ Galafold for treating the rare genetic disorder Fabry disease.
Read More
SMC endorses use of five meds on NHS Scotland
The Scottish Medicines Consortium has endorsed the use of five new therapies by NHS Scotland to treat melanoma, ovarian cancer, hepatitis C, Fabry disease and bacterial vaginosis.
Read More
NICE backs new therapy for Fabry disease
Cost regulators for the NHS in England and Wales are backing use of a new therapy to treat the rare genetic disorder Fabry disease with a price tag of £210,000 per patient per year (excluding VAT and any discounts).
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
